DI-034 Drug usage evaluation of abiraterone in metastasic castration resistant prostate cancer: 4 Years of experience

@inproceedings{Palomares2016DI034DU,
  title={DI-034 Drug usage evaluation of abiraterone in metastasic castration resistant prostate cancer: 4 Years of experience},
  author={Mv Villaca{\~n}as Palomares and Em S{\'a}ez Fern{\'a}ndez and Glenn M. Garcia and Elena Fernandez Dominguez and Mv Calvo Hern{\'a}ndez},
  year={2016}
}
Background Abiraterione is an expensive drug indicated for the treatment of metastasic castration resistant prostate cancer. In order to optimise its use, abiraterone is authorised for use under certain criteria in our hospital. Purpose To analyse compliance with detailed criteria, response to and safety of abiraterone in clinical practice in a tertiary hospital. Material and methods Retrospective observational study of all patients who received abiraterone for 4 years (January 2011–December… CONTINUE READING